Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.17    -0.015 (-8.11%)
Bid:
0.16
Ask:
0.18
Spread: 0.02 (12.50%)
Market Cap: £2.24m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Directorate Change

12 May 2006 14:49

Azure Holdings PLC12 May 2006 Azure Holdings plc (the "Company") Board changes The Company announces the appointment of Barry Gold and Gerald Desler asdirectors of the Company, and the resignation of the existing directors,Nicholas Greenstone and Ronald Stirling, with immediate affect. Barry Gold, age 58, is a solicitor with experience of fully listed andAIM-quoted companies. Mr Gold is currently the chairman and joint managingdirector of Premier Management Holdings plc, an AIM-quoted football agency. Mr Gold's current directorships are as follows: BG Consultancy Services Limited, Matisse Holdings plc, Nemesis Marketing Groupplc, Premier Management Holdings plc, Premier Management Recruitment Limited,Premier Management Snooker Limited, Venture Six plc. In the past five years Mr Gold has been a director of the following companies: Aimwright Limited, Apollo Metals plc, Avent Limited, Avent Enterprises Limited,Bracken Partners Limited, Bracken Partners Group Limited, Cannon Avent Groupplc, Cannon Avent Limited, Capitol Group plc, Dudley Jenkins Group plc, EssexFurniture plc (1), Hopeflow Properties Limited, Kingstonian Football ClubLimited, London Asia Capital plc, Moving Homes Limited, Non-League Media plc(2), Pure Holdings Limited, Southern Homes & Properties Limited, TimeframedLimited (3), Underwriting and Subscription plc, Yorkplan Limited. (1) Mr Gold was a non-executive director at the time of or within the 12 monthspreceding the administrative receivership of Essex Furniture plc which occurredin October 1998. At the time the administration order was made for EssexFurniture plc in October 1998, the estimated deficiency with regards tocreditors was £17,044,308. The majority of this related to estimated rents duein respect of the remaining terms of leases, all but two of which by December1999 had either been assigned or returned to the landlords; customers' deposits,where the goods have now been substantially delivered; and a VAT repayment of£2.35 million. (2) Mr Gold was also a non-executive director at the time of or within the 12months preceding the administrative receivership of Non-League Media plc, whichoccurred in June 2002. At the time the administration order was granted, theestimated deficiency with regards to creditors was £116,999. (3) Mr Gold was also a non-executive director at the time of or within the 12months preceding the insolvent liquidation of Timeframed Limited, which occurredin November 2001. At the time of the appointment of the liquidator to TimeframedLimited, the deficiency as regards to creditors was £8,361,386, of which£4,500,000 was in respect of loan stock holders; £3,000,000 was owed to thefounder; £41,512 to preferential creditors; and £423,586 to unsecured creditors. Mr Gold was a non-executive director at the time of or within the 12 monthspreceding the administrative receivership of Clearmark Group plc, which occurredin August 1991. The receivers ceased to act for Clearmark Group plc in 1998,which was subsequently dissolved by notice in the London Gazette, dated 20 April1999. Gerald Desler, age 60, is a chartered accountant, who qualified in 1968 withStanley A Spofforth & Co., becoming a partner in 1970 and a senior partner in1985. Mr Desler is currently the finance director of Premier Management Holdingsplc. Mr Desler's current directorships are as follows: 140 High Street Management Limited, Andrew Manning Limited, Andrew MillsConsultancy Limited, Aralbest Limited, Babble.net Group plc, BG ConsultancyServices Limited, C&R Civil Enforcement Services Limited (4), Click 4 SupportLimited, Desler Consulting Limited, Managed Services Solutions Limited, MSCAgency Limited, Premier Management Football Limited, Premier Management Holdingsplc, Premier Management Recruitment Limited, Southern Homes & PropertiesLimited, Sports Player Management Limited (5), Student Link plc, Tangent MediaGroup Limited, Venture Six plc, In the past five year's Mr Desler has been a director of the following: Global Screen Ad Services Limited, Global Screen Ad Systems Limited, KingstonianFootball Club Limited, Milefarm Limited, Noviceguru Limited, Resday Limited,Signactual Limited, The Online Shop Web Fulfilment Limited, Theonlineshop.co.ukLimited, Theonlineshop.TV Limited, Yorkplan Limited (4) On 9 August 2001, Mr Desler was appointed a director of C&R CivilEnforcement Services Limited. A liquidator was appointed on 18 October 2004. Theliquidation is ongoing. (5) Mr Desler is a director of Sports Player Management Limited which went intoliquidation in April 2006. The liquidation is ongoing. Mr Desler was a director of Grovefair plc, which went into voluntaryreceivership in March 1997. He had resigned as a director on 31 March 1996.Following his resignation as a director of Grovefair plc, it undertook areorganisation whereby it was divided into two separately owned entities. WhileGrovefair plc went into voluntary receivership, the other entity did not. There are no further disclosures required under Schedule Two (g) of the AIMrules. For further information please contact: Barry Gold, Azure Holdings plc Tel: 07768 948 928David Youngman, WH Ireland Limited Tel: 0161 832 2174 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
26th Jun 201912:00 pmRNSHolding(s) in Company
26th Jun 20197:00 amRNSUS Notice of Allowance-VAL201 & Metastatic Cancer
25th Jun 20192:50 pmRNSFurther re: Termination of Subscription Agreement
24th Jun 201912:45 pmRNSHolding(s) in Company
21st Jun 201912:00 pmRNSHolding(s) in Company
20th Jun 20197:00 amRNSUpdate on VAL201 Clinical Trial
19th Jun 201912:00 pmRNSHolding(s) in Company
13th Jun 20197:00 amRNSPlacing, Subscription Agreement & Issue of Warrant
10th Jun 20197:00 amRNSSubscription Agreement Update
5th Jun 20197:00 amRNSNotice of AGM & Update of Subscription Agreement
31st May 201911:07 amRNSSubscription Agreement Update
31st May 201910:42 amRNSHolding(s) in Company
30th May 201910:30 amRNSHolding(s) in Company
29th May 201911:44 amRNSHolding(s) in Company
29th May 20197:00 amRNSFinal Results
28th May 20197:00 amRNSSubscription Agreement Update
23rd May 201912:02 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription Agreement Update
13th May 20192:00 pmRNSPrice Monitoring Extension
2nd May 20197:00 amRNSAcquisition of Intellectual Property& JV Agreement
29th Apr 20192:06 pmRNSSecond Price Monitoring Extn
29th Apr 20192:01 pmRNSPrice Monitoring Extension
29th Apr 201911:07 amRNSSecond Price Monitoring Extn
29th Apr 201911:01 amRNSPrice Monitoring Extension
29th Apr 201910:55 amRNSHolding(s) in Company
26th Apr 20197:00 amRNSSubscription, Convertible Funds and Warrant Issue
15th Apr 20197:15 amEQSHardman & Co Research: Valirx (VAL): VAL401 is going forward
26th Mar 20197:00 amRNSValiSeek Update
21st Mar 20197:00 amRNSUpdate on VAL201 & VAL301 Development Progress
21st Feb 201911:22 amRNSPlacing, Issue of Equity and Warrant
31st Jan 20197:00 amRNSNew patent grant allowances for VAL301
11th Jan 20197:00 amRNSPublication of VAL401 peer-reviewed article
9th Jan 201910:41 amRNSValiRx endorses the Government's new NHS strategy
3rd Jan 20197:00 amRNSHolding(s) in Company
18th Dec 20184:41 pmRNSSecond Price Monitoring Extn
18th Dec 20184:36 pmRNSPrice Monitoring Extension
18th Dec 201811:25 amRNSIssue of Equity / PDMR Shareholdings
18th Dec 20187:00 amRNSUpdate on VAL401 - Peer-review Acceptance
10th Dec 20187:00 amRNSUpdate on VAL201 Clinical Trial
5th Nov 20187:00 amRNSRe scientific and investor meetings
1st Nov 20187:15 amEQSHardman & Co Research: ValiRx (VAL): VAL401 Phase II trial completed
24th Oct 20187:00 amRNSAlign Research Initiates Coverage
17th Oct 20187:00 amRNSVAL201 in concluding stages of Phase I/II trial
15th Oct 201812:00 pmRNSVAL401 results shortly to be on ClinicalTrials.gov
25th Sep 20187:00 amRNSHalf-year Report
14th Sep 201812:42 pmRNSIssue of Equity
6th Sep 20187:00 amRNSUpdate on Clinical Development
24th Jul 201812:17 pmRNSResult of General Meeting
17th Jul 20187:00 amRNSUS PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
6th Jul 20184:42 pmRNSNotice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.